Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

NCT05602935 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Fujian Medical University as lead sponsor.

NCT NCT05602935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05602935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
Lead sponsor
The Second Affiliated Hospital of Fujian Medical University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 16, 2020
Completion date
December 30, 2026
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system diseases, digestive system neoplasms, neoplasms, neoplasms by site, stomach diseases, stomach neoplasms